-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Business and Investments
Latest From Business and Investments
Positive Phase 2 results for TOPICA’s luliconazole
TOPICA Pharmaceuticals had positive results from its Phase 2 clinical study evaluating luliconazole, a topical antifungal agent, in patients with tinea pedis (athlete’s foot). The study assessed the effectiveness of luliconazole cream applied once daily for 14 days compared with once daily for 28 days.
Long-term immune response for Vical’s TransVax™ vaccine in Phase 2 trial
Vical Incorporated (Nasdaq:VICL) announced that TransVax™ cytomegalovirus vaccine continued to demonstrate an overall increase in cellular immune responses compared with placebo at the seven-month immunogenicity data point in an ongoing Phase 2 trial.
Inovio reports clinical trial progress of cervical cancer vaccine
Inovio Biomedical Corporation (NYSE Amex: INO) announced safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus types 16 and 18 and is delivered via in vivo electroporation. The vaccine was found to be generally safe and well tolerated, and achieved significant cellular and humoral immune responses at the lowest dose administered. Read the release.
Immunovaccine begins trading as “IMV”
Immunovaccine Inc. (TSX-V:IMV) will begin trading on the TSX-Venture Exchange as a Tier 1 issuer under the ticker symbol “IMV”. Immunovaccine Inc. also announces the closing of the previously announced private placement totaling $8,269,109 in gross proceeds. The TSX Venture Exchange has accepted the private placement for filing. Read the release.
Oncolytics enters into agreement with FDA for Phase 3 trial of REOLYSIN®
Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) has reached an agreement with the FDA under the Special Protocol Assessment (SPA) process for the design of a Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. The SPA is an agreement between Oncolytics and the FDA that the design and planned analyses of the Phase 3 study is adequately designed to provide the necessary data, that depending Read More >
